Abstract
Effect of Neoadjuvant Chemoradiotherapy on Pathologic Stage and Survival in Patients with Locally Advanced Esophageal Cancer
Highlights
Esophageal cancer comprises a small percentage (1.5%) of total cancer cases in the United States, mortality rate remains high
Cisplatin/5-FU-based neoadjuvant chemoradiotherapy for resectable esophageal cancer leads to pathologic downstaging in most patients, and lower pathologic stage correlates with better survival
The goal of this study is to evaluate pathologic stage as a categorical variable for predicting survival in patients with locally advanced esophageal cancer treated with pre-operative CRT and to determine whether pathologic stage better predicted outcome than pretreatment clinical stage
Summary
Esophageal cancer comprises a small percentage (1.5%) of total cancer cases in the United States, mortality rate remains high. In the United States, an estimated 16,980 cases of esophageal cancer will be diagnosed in 2015 and 15,590 deaths are expected from the disease [1,2]. At most 10-15% of all patients presenting with esophageal cancer are cured [3] For those with locally advanced, non-metastatic disease, cure is achieved in up to 40% of patients when multimodality therapy is used [4,5]. The treatment of resectable stages of esophageal cancer often involves pre-operative concurrent chemoradiotherapy. This study aims to evaluate the effect of cisplatin/5-fluorouracil (5-FU)-based neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
